IPO Year: 2021
Exchange: AMEX
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/22/2023 | $11.00 | Buy | H.C. Wainwright |
10/9/2023 | $9.00 | Outperform | Robert W. Baird |
Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma CLD-101 is Calidi's novel allogeneic immunotherapy utilizing neural stem cells to deliver engineered oncolytic adenoviruses Phase 1b/2 trial expected to initiate in the first quarter of 2025 SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared Northwestern University's Investigational New Drug (IND) application for Calidi's CLD-101. CLD-101 is a novel stem-cell bas
Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi's Adult Adipose Allogeneic (AAA) stem cell innovative programs Strengthened team with the appointment of Dr. George E. Peoples, MD, FACS, adjunct professor of Surgical Oncology at MD Anderson Cancer Center, to the company's Board of Directors, and the addition of Mark Gilbert, MD, scientist emeritus at the National Institutes of Health (NIH), to its Medical Advisory Board Received a new U.S. patent for the company's novel SuperNova technology, positioning Calidi to advance its CLD-201 program into the clinic. The patent covers a unique cancer treatment combining stem cells and a smallpox vaccin
ORLANDO, FL / ACCESSWIRE / August 2, 2024 / RedChip Companies will air interviews with GreenPower Motor Company Inc. (NASDAQ:GP) and Calidi Biotherapeutics, Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 3, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:GreenPower Motor: https://www.redchip.com/assets/access/gp_accessCalidi Biotherapeutics: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Fraser Atkinson, CEO of GreenPower, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the issuance of a new patent for the company's SuperNova technology, strengthening its intellectual property portfolio and positioning Calidi to advance its CLD-201 program into the clinic. The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,036,278 titled, "Smallpox Vaccine for Cancer Treatment," directed to Calidi's SuperNova platform composed of adipose-derived mesenchymal stem cells loaded with oncolytic vaccinia virus. "This latest patent grant
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Mark Gilbert, MD, scientist emeritus at the National Institutes of Health (NIH), to its Medical Advisory Board. This addition increases the board's membership to eight. Dr. Gilbert most recently served as the Chief of the Neuro-Oncology Branch at NIH from 2014 to 2024. Under Dr. Gilbert's leadership, his team of laboratory and clinical investigators conducted groundbreaking research that advanced science in the brain tumor field. He developed robust clinical tria
Calidi common stock expected to begin trading on a 1-for-10 split adjusted basis on July 15, 2024 Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi" or "Company"), a clinical-stage biotechnology company developing a new generation of targeted virotherapies, today announced that its Board of Directors has approved the reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10 (the "Reverse Stock Split"). The Reverse Stock Split is expected to become effective at 12:01 a.m. Eastern Time on July 15, 2024. The Company's common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on July 15, 2024 under the existing symbol
Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Dr. George E. Peoples, MD, FACS, to the company's Board of Directors, effective July 1, 2024. "Dr. Peoples is a highly esteemed figure in the field of cancer immunotherapy, bringing decades of experience in cancer vaccine development and clinical research to our Board," said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. "Dr. Peoples' pioneering work in cancer immunotherapy and his extensive experience in both clinical and military settings will be invaluable as we advance our portfolio
Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, is pleased to invite investors to a webinar on June 13, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Calidi Biotherapeutics Chief Business Officer, Stephen Thesing, and Chief Financial Officer, Andrew Jackson, who will share insight into the Company's proprietary technology platforms and current development pipeline. Calidi is at the forefront of oncolytic virotherapy (OV), a promising multi-billion-dollar area in cancer treatment. Calidi is pioneering the development of both systemi
Calidi's best-in-class, novel systemic targeted virotherapy program (RTNova) aims to provide a feasible solution to target disseminated tumors with a systemic administration -- a long-pursued breakthrough by the biopharma industry. RTNova utilizes a potent vaccinia virus enveloped by a human cell membrane, designed to evade human immunity and enhance its therapeutic functions. RTNova's novel therapeutic approach allows for ease of administration and the ability to reach a broad patient population. SIGA will supply TPOXX® (Tecovirimat), an effective antiviral agent against vaccinia virus, to support the development of RTNova and accelerate development of extracellular enveloped vac
- NeuroNova (CLD-101) Phase 1 update highlights enrollment progress, safety and feasibility in delivering up to four weekly doses of CLD-101 - Showcased preclinical data on RTNova (CLD-400) platform's ability to survive bloodstream and reach all tumors systemically - Non-clinical data supporting the upcoming SuperNova (CLD-201) clinical trial Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the presentation of three abstracts in a poster session during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These posters, presented on June 1, 2024, include a
SC 13G - Calidi Biotherapeutics, Inc. (0001855485) (Subject)
H.C. Wainwright initiated coverage of Calidi Biotherapeutics with a rating of Buy and set a new price target of $11.00
Robert W. Baird initiated coverage of Calidi Biotherapeutics with a rating of Outperform and set a new price target of $9.00
S-3 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
S-8 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
10-Q - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
ORLANDO, FL / ACCESSWIRE / August 2, 2024 / RedChip Companies will air interviews with GreenPower Motor Company Inc. (NASDAQ:GP) and Calidi Biotherapeutics, Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 3, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:GreenPower Motor: https://www.redchip.com/assets/access/gp_accessCalidi Biotherapeutics: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Fraser Atkinson, CEO of GreenPower, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to
ORLANDO, FL / ACCESSWIRE / May 24, 2024 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and Calidi Biotherapeutics Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 25, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ASP Isotopes: https://www.redchip.com/assets/access/aspi_accessCalidi Biotherapeutics: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Paul Mann, CEO of ASP Isotopes, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate u
ORLANDO, FL / ACCESSWIRE / May 17, 2024 / RedChip Companies will air interviews with Calidi Biotherapeutics Inc. (NYSE:CLDI) and Unusual Machines Inc. (NYSE:UMAC) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 18, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Calidi Biotherapeutics: https://www.redchip.com/assets/access/cldi_accessUnusual Machines: https://www.redchip.com/assets/access/umac_accessIn an exclusive interview, Allan Camaisa, Chief Executive Officer of Calidi Biotherapeutics, appears on the RedChip Small Stocks, Big Money™ show
Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi's Adult Adipose Allogeneic (AAA) stem cell innovative programs Strengthened team with the appointment of Dr. George E. Peoples, MD, FACS, adjunct professor of Surgical Oncology at MD Anderson Cancer Center, to the company's Board of Directors, and the addition of Mark Gilbert, MD, scientist emeritus at the National Institutes of Health (NIH), to its Medical Advisory Board Received a new U.S. patent for the company's novel SuperNova technology, positioning Calidi to advance its CLD-201 program into the clinic. The patent covers a unique cancer treatment combining stem cells and a smallpox vaccin
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Mark Gilbert, MD, scientist emeritus at the National Institutes of Health (NIH), to its Medical Advisory Board. This addition increases the board's membership to eight. Dr. Gilbert most recently served as the Chief of the Neuro-Oncology Branch at NIH from 2014 to 2024. Under Dr. Gilbert's leadership, his team of laboratory and clinical investigators conducted groundbreaking research that advanced science in the brain tumor field. He developed robust clinical tria
Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Dr. George E. Peoples, MD, FACS, to the company's Board of Directors, effective July 1, 2024. "Dr. Peoples is a highly esteemed figure in the field of cancer immunotherapy, bringing decades of experience in cancer vaccine development and clinical research to our Board," said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. "Dr. Peoples' pioneering work in cancer immunotherapy and his extensive experience in both clinical and military settings will be invaluable as we advance our portfolio
City of Hope, a leader in cancer research and treatment, was awarded $5.3 million from California Institute for Regenerative Medicine (CIRM) to develop a treatment for metastatic ovarian cancer using Calidi's licensed lead asset, NeuroNova (CLD-101) Announced novel systemic enveloped oncolytic virotherapy platform, RTNova, designed to target diverse tumor types Strengthened team with the appointment of three new members to Scientific and Medical Advisory Board and one member to Board of Directors Issued new U.S. patent covering novel SuperNova (CLD-201) technology platform Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a ne
Antonio Chiocca, M.D., Ph.D., Chair, Department of Neurosurgery at Brigham and Women's Hospital, Co-Director, Institute for the Neurosciences, and Professor of Neurosurgery at Harvard Medical School David T. Curiel, M.D., Ph.D., Professor of Radiation Oncology at the Washington University School of Medicine Burt L. Nabors, M.D., Professor, Vice Chair for Research, and Division Director of Neuro-Oncology at the University of Alabama at Birmingham Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board. The
Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the appointment of David LaPré to the company's Board of Directors effective January 1, 2024. The company also announced the resignation of Director Alfonso Zulueta effective November 29, 2023 and the resignation of Director Tom Vecchiolla effective January 1, 2024. "David LaPré brings a wealth of pharmaceutical industry experience, expertise in solving problems unique to this industry, and a solid understanding of the factors that drive shareholder value. His past experiences will help Calidi move forward as a company, advancing our por
Announced first patient dosed by collaborator City of Hope in a Phase 1 clinical trial evaluating CLD-101 in recurrent high-grade glioma patients Presented new preclinical data highlighting CLD-201 (SuperNova) platform technology at SITC 2023 Strengthened leadership with key appointments to management team and Board of Directors Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, reports its financial results for the third quarter 2023 and reviews recent business highlights. "We are highly encouraged by our clinical progress, highlighted by our partner City of Hope dosing the first patient in June
Antonio F. Santidrian, PharmD, Ph.D., promoted to Chief Scientific Officer and Amish Patel, Ph.D., promoted to Senior Vice President of Technical Operations Alan Stewart appointed to Board of Directors Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced two key promotions from the clinical leadership team and the appointment of a new Board Director. Antonio Santidrian, PharmD, Ph.D., previously Senior Vice President, Global Head of Research and Development, has been promoted to Chief Scientific Officer and Amish Patel, Ph.D., has been promoted to Senior Vice President of Technical Opera
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
3 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the issuance of a new patent for the company's SuperNova technology, strengthening its intellectual property portfolio and positioning Calidi to advance its CLD-201 program into the clinic. The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,036,278 titled, "Smallpox Vaccine for Cancer Treatment," directed to Calidi's SuperNova platform composed of adipose-derived mesenchymal stem cells loaded with oncolytic vaccinia virus.
https://ppubs.uspto.gov/pubwebapp/external.html?q=(12036278).pn
Shares of Arhaus, Inc. (NASDAQ:ARHS) fell sharply during Monday's session. Jefferies analyst Jonathan Matuszewski downgraded Arhaus from Buy to Hold and lowered the price target from $22 to $16. Arhaus shares dipped 7.9% to $14.55 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Morphic Holding, Inc. (NASDAQ:MORF) shares jumped 75% to $55.72 after Eli Lilly agreed to buy the company for $57 per share in cash. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) climbed 71% to $6.97 after jumping around 50% on Friday. SRIVARU Holding Limited (NASDAQ:SVMH) shares climbed 61.3% to $0.2549 after the company announced the deployment of advanced
Calidi Biotherapeutics Inc (NASDAQ:CLDI) shares are trading lower by 14.3% to $0.17 during Monday’s session after the company announced a 1-for-10 reverse stock split, effective at 12:01 a.m. Eastern Time on July 15. The company’s common stock will begin trading on a split-adjusted basis on the NYSE American market under the symbol “CLDI”. The reverse stock split was approved by the company’s stockholders at a Special Meeting on June 6, and finalized by the Board on July 1. As a result, the number of issued and outstanding shares of common stock will be reduced to one-tenth of the pre-split amount, with fractional shares rounded up to the nearest whole share. The reverse stock split will
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Calidi Biotherapeutics (AMEX:CLDI) with a Buy rating and announces Price Target of $1.
Shares of Streamline Health Solutions, Inc. (NASDAQ:STRM) fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter EPS results. Streamline Health reported quarterly losses of 5 cents per share which missed the analyst consensus estimate of 4 cents per share. The company reported quarterly sales of $4.33 million which beat the analyst consensus estimate of $4.31 million, according to data from Benzinga Pro. Streamline Health Solutions shares dipped 23.3% to $0.4902 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers DDC Enterprise Limited (NYSE:DDC) surged 101% to $1.04. DDC Enterprise said it has acqu
Gainers Longeveron (NASDAQ:LGVN) shares rose 112.1% to $1.74 during Wednesday's regular session. The market value of their outstanding shares is at $11.0 million. vTv Therapeutics (NASDAQ:VTVT) stock increased by 43.09% to $26.0. The market value of their outstanding shares is at $63.2 million. Avidity Biosciences (NASDAQ:RNA) shares increased by 32.32% to $38.27. The company's market cap stands at $3.6 billion. Cyclerion Therapeutics (NASDAQ:CYCN) stock rose 30.39% to $2.96. The company's market cap stands at $7.3 million. Telesis Bio (NASDAQ:TBIO) stock moved upwards by 22.53% to $3.86. The company's market cap stands at $6.4 million. Autonomix Medical (NASDAQ:AMIX) stock rose 20.94%
Gainers Avidity Biosciences (NASDAQ:RNA) shares rose 24.5% to $36.0 during Wednesday's pre-market session. The company's market cap stands at $3.4 billion. Molecular Partners (NASDAQ:MOLN) shares moved upwards by 18.43% to $5.91. The market value of their outstanding shares is at $196.1 million. Longeveron (NASDAQ:LGVN) shares increased by 15.84% to $0.95. The company's market cap stands at $6.0 million. TRACON Pharma (NASDAQ:TCON) shares increased by 15.74% to $1.25. The market value of their outstanding shares is at $3.3 million. Oramed Pharmaceuticals (NASDAQ:ORMP) stock moved upwards by 14.49% to $2.37. The market value of their outstanding shares is at $96.2 million. NovaBay Pharm